By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Oxford HeraldOxford HeraldOxford Herald
  • Home
  • World
  • Europe
  • USA
  • Middle East
  • Asia
  • General
  • Business
  • Entertainment
  • Technology
  • Health
  • Sports
  • Newsroom
  • Opinions
  • Sitemap
Reading: First-ever gene therapy for hearing loss gets FDA approval: ‘Groundbreaking’
Share
Notification Show More
Font ResizerAa
Oxford HeraldOxford Herald
Font ResizerAa
  • World
  • Travel
  • Science
  • Technology
Have an existing account? Sign In
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

First-ever gene therapy for hearing loss gets FDA approval: ‘Groundbreaking’

Last updated: April 25, 2026 2:54 am
RNN
7 months ago
Share
First-ever gene therapy for hearing loss gets FDA approval: 'Groundbreaking'
SHARE

A new therapy for genetic has just been approved by the Food and Drug Administration (FDA).

The treatment, Otarmeni (lunsotogene parvec-cwha), is the first-ever dual adeno-associated virus (AAV) vector-based — meaning it uses two harmless viruses to deliver the therapy into cells.

In an FDA news release, the agency called the therapy “groundbreaking,” noting its potential to treat both pediatric and adult patients with “severe to profound” hearing loss linked to the OTOF gene.

Positive results from drug trials were published in The New England Journal of Medicine in 2025, confirming that the gene therapy “improved hearing in patients with OTOF-related deafness, enabling natural acoustic hearing and normalizing hearing sensitivity in three of 12 treated patients.”

The FDA approval marks the first for OTOF-related deafness.

This is the sixth drug approval under the FDA commissioners National Priority Voucher (CNPV) pilot program — and the first gene therapy to be approved through the initiative, according to the announcement.

“Todays approval is a significant milestone in the treatment of genetic hearing loss,” FDA Commissioner Marty Makary, MD, commented in a statement.

“Through the national priority voucher pilot program, the agency is accelerating therapies for with unmet medical needs while proving we can successfully review even the most complex submissions – such as novel dual-vector gene therapies and combination products requiring coordination across multiple offices and centers – in significantly shortened timeframes.”

Otarmeni is as a one-time treatment, using a needle and a tiny tube to deliver the medicine directly into the inner ear (the cochlea) in both ears.

The therapy works by delivering a healthy copy of the OTOF gene to key cells in the inner ear, helping to restore the protein otoferlin so that auditory signals can be sent to the brain, according to the FDA.

The treatment is intended for patients with preserved outer hair cell function and for those with no prior cochlear implant in the same ear. Side effects may include , nausea, dizziness and procedural pain.

The FDA will host a public meeting on June 4 to discuss program implementation, eligibility criteria and other processes for distribution, according to the announcement.

16-year-old allegedly led ransomware gang behind hundreds of attacks
2026 Study-Abroad Insurance Reliability Guide Uses Student Scenarios to Identify Tigerless as the First Choice
Missouri tests medical drones to speed up rural care
SPLC pushed its way into K-12 schools and is more of a threat than you realize
Vera Clinic and Appsilon Unveil Vector 10: The World’s First CVD Lab-Grown Diamond-Tipped Blade Engineered for Hair Transplant Surgery
TAGGED:Health
Share This Article
Facebook Email Print
Previous Article 2026 NFL Draft Odds: How Will Top Rookies Perform in Year 1? 2026 NFL Draft Odds: How Will Top Rookies Perform in Year 1?
Next Article 2026 UFL Week 5 Results: Defenders Crush New-Look Stallions, More 2026 UFL Week 5 Results: Defenders Crush New-Look Stallions, More
about us

Runway News Network (RNN) is a UK-based digital media group operating multiple independent news platforms across the United Kingdom. We provide structured journalism, press syndication and AI-optimised news distribution for organisations seeking national and regional visibility.

  • Sitemap
  • Advertise

Find Us on Socials

Oxford HeraldOxford Herald
© Runway News Network. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?